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Objectives: The aim of this study was to evaluate the diagnostic performance of serum HA 
and LN as serum markers for predicting significant fibrosis in CHB patients. 
Methods: Serum HA and LN levels of 87 patients with chronic hepatitis B and 19 blood 
donors were assayed by RIA. Liver fibrosis stages were determined according to the Metavir 
scoring-system. The diagnostic performances of all indexes were evaluated by the receiver 
operating characteristic (ROC) curves. 
Results: Serum HA and LN concentrations increased significantly with the stage of hepatic 
fibrosis, which showed positive correlation with the stages of liver fibrosis (HA: r = 0.875, 
p < 0.001; LN: r = 0.610, p < 0.001). There were significant differences of serum HA and LN 
levels between F2-4 group in comparison with those in F0-F1 group (p < 0.001) and controls 
(p < 0.001), respectively. From ROC curves, 185.3 ng/mL as the optimal cut-off value of serum 
HA for diagnosis of significant fibrosis, giving its sensitivity, specificity, PPV, NPV, LR+, 
LR- and AC of 84.2%, 83.3%, 90.6%, 73.5%, 5.04, 0.19 and 83.9, respectively. While 132.7 ng/mL 
was the optimal cut-off value of serum LN, the sensitivity, specificity, PPV, NPV, LR+, LR- 
and AC were 71.9%, 80.0%, 87.2%, 60.0%, 3.59%, 0.35% and 74.7, respectively. Combinations 
of HA and LN by serial tests showed a perfect specificity and PPV of 100%, at the same 
time sensitivity declined to 63.2% and LR+ increased to 18.9, while parallel tests revealed a 
good sensitivity of 94.7%, NPV to 86.4%, and LR- declined to 0.08. 
Conclusions: Serum HA and LN concentrations showed positive correlation with the stages 
of liver fibrosis. Detection of serum HA and LN in predicting significant fibrosis showed 
good diagnostic performance, which would be further optimized by combination of the 
two indices. HA and LN would be clinically useful serum markers for predicting significant 
fibrosis in patients with chronic hepatitis B, when liver biopsy is contraindicated. 
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Introduction
The prognosis and clinical treatment of chronic liver disease 
depends greatly on the progression of liver fibrosis, which 
is resulted from the loss of normal liver cell function due 
to disorganized over-accumulation of extra-cellular matrix 
(ECM) components in the liver.1-4 In China, especially in 
our province, chronic hepatitis B is one of the main causes 
of chronic liver disease. Therefore it is clinically important 
to assess the progression of liver fibrosis for guiding clinical 
therapy.5 For many years, liver biopsy has been considered 
the gold standard for staging and grading hepatic fibrosis 
and inflammation.1,6 However, the procedure is associated 
with complications such as bleeding, infection, damage to liver 
tissue, etc,6,7 and it is difficult to put into practice. Currently, 
with the improvements in treatment modalities for chronic 
liver disease, there is an increasing need for rapid, safe and 
reliable noninvasive diagnostic methods to stage liver fibrosis, 
and some of which have been widely validated in patients with 
chronic hepatitis.7-15
The ECM components in the liver include non-collagenous 
glycoproteins such as hyaluronic acid (HA), laminin (LN) and 
proteoglycans, etc. In the liver, HA is a glycosaminoglycan, 
which is mostly synthesized by hepatic stellate cells and 
degraded by sinusoidal endothelial cells.16 LN is synthesized 
by hepatocytes and sinusoidal cells, which is one of the main 
glycoproteins of the basement membrane.17 Reports showed 
that serum fibrosis indices, including HA and LN, could reflect 
the activity of liver fibrosis to some extent.6,18-26
In this study, we aimed to evaluate serum HA and LN levels 
as potential indicators of significant fibrosis in patients with 
chronic hepatitis B according to the Metavir scoring-system, 
as well as to assess the diagnosis performance of combination 
of the two indices.
Methods
Subjects
Eighty-seven patients with chronic hepatitis B, who were 
diagnosed by positive serologic tests for serum hepatitis B 
surface antigen for at least 6 months, were all from Affiliated 
Hospital of Nantong University, including 49 men and 38 
women, median age (25th percentile; 75th percentile) 38.4 
(34.1;49.9). These patients were included in this study with 
an indication for percutaneous liver biopsy, which was 
performed for assessment of the severity of liver fibrosis. Liver 
transplantation, gastrointestinal bleeding and other chronic 
liver diseases were excluded. Sera of  19 blood donors was used 
as a control group, including 10 men and 9 women, median 
age (25th percentile; 75th percentile): 30.1(28.1; 33.9). Healthy 
subjects had normal serum levels of regular biochemical 
parameters such as alanine aminotransferase (ALT), aspartate 
aminotransferases (AST) and alkaline phosphatase (ALP), etc, 
and with no chronic liver diseases.
All patients provided written informed consent to 
participate in the study and Affiliated Hospital of Nantong 
University Ethical Committee approved the study.
Histology
All liver biopsies were performed with a suction needle 
(18G, Angiomed Corporation – German). Ultrasound was 
routinely used to determine the percutaneous biopsy site. 
The size of liver biopsy specimen exceeded 1 cm. The liver 
tissue sections were fixed in 10% neutralized formadehyde, 
embedded in paraffin and stained with hematoxylin-eosin, 
Mason-Trichrome, and Perls-iron. All biopsy specimens were 
analyzed by an experienced pathologist blinded to the clinical 
results of the patients. Liver fibrosis stages were evaluated 
semi-quantitatively according to the Metavir scoring-system.27 
Fibrosis was staged on a scale of 0 to 4: F0 = no fibrosis, 
F1 = portal fibrosis without septa, F2 = portal fibrosis and few 
septa, F3 = numerous septa without cirrhosis, F4 = cirrhosis. 
Determination of serum specimens
All serum specimens from 87 patients with chronic hepatitis 
B were stored at -20oC. Levels of serum HA and LN were 
analyzed by RIA and determined from a standard curve. 
Kits of HA and LN were provided all by the Shanghai Navy 
Medical Institute. The procedures were performed according 
to the user’s manual. Liver function indexes were measured 
by an automatic biochemistry analyzer, including ALT, AST, 
ALP, total bilirubin (TBIL), γ-glutamyltransferase (GGT) and 
albumin (ALB).
Statistical analysis
The SPSS statistical package software (version 12.0) was used 
for statistical analysis.
Data are reported as the median with 25th and 75th 
percentiles of marker concentrations. Independent-samples 
t-test was used for analysis of the differences between 
two groups. Kruskal–Wallis one-way analysis of variance 
(ANOVA) was performed for comparing with the differences 
between patient subgroups (five stages of liver fibrosis) and 
healthy controls. Correlations were assessed by Spearman’s 
correlation coefficient.
A two tailed p-value less than 0.05 was considered 
statistically significant. Sensitivity, specificity, positive 
and negative predictive values, positive and negative 
l i k e l i h o o d  r a t i o  a n d  d i a g n o s t i c  a c c u r a c y  w e r e 
calculated according to the following formula ( in 
which a = true-positive cases, b = false-positive cases, 
c = false-negative cases, and d = true-negative cases): 
sensitivity = a/(a + c), specificity = d/(b + d), diagnostic 
accuracy = (a +d)/(a + b + c + d), positive predictive 
value = a/(a + b), negative predictive value = d/(c + d), 
positive likelihood ratio = sensitivity/(1- specificity), negative 
likelihood ratio = (1- sensitivity)/specificity.
The ROC curves were constructed to study the absence and 
presence of significant fibrosis (F ≥ 2). The cut-off values were 
determined with ROC curve procedure.28
 BRAZ J INFECT DIS. 2012;16(1):9-14 11
Results
According to the Metavir scoring-system, the fibrosis 
stages on liver biopsy was F0 in 13 patients (14.9%), F1 
in 17 (19.5%), F2 in 25 (28.7%), F3 in 23 (26.4%), and F4 in 
9 (10.3%) in this study. Thus, a total of 57 patients (65.5%) 
had significant fibrosis (≥ F2). The results through box 
plots showed that serum HA and LN concentrations 
increased signif icantly  with the stage of  hepatic 
fibrosis (Figs. 1 and 2), and the highest values of HA 
and LN were all found in cirrhotic patients. HA and 
LN levels showed positive correlation with the stages 
of liver fibrosis (HA: r = 0.875, p < 0.001; LN: r = 0.610, 
p < 0.001). The serum HA and LN concentrations did not 
differ significantly between the control group and the F0 
group (HA: p = 0.604; LN: p = 0.059).
For significant fibrosis (F ≥ 2), Figs. 3 and 4 show the 
distribution of HA and LN concentrations in controls and 
CHB patients by fibrosis stage (F0-F1, F2-F4), respectively. 
Significant differences of serum HA and LN levels were found 
in F2-F4 group in comparison with those in F0-F1 group 
(p < 0.001) and controls (p < 0.001), respectively.
To predict significant fibrosis (F ≥ 2), the area under the curve 
(AUC) for serum HA and LN was 0.909 (95% CI: 0.847–0.971) and 
0.815 (95% CI: 0.712–0.917), respectively (Fig. 5). The difference 
was not statistically significant (p = 0.743). The results showed 
that 185.3 ng/mL was the optimal cut-off value of serum HA for 
diagnosis of significant fibrosis, giving its sensitivity, specificity, 
PPV, NPV, LR+, LR- and AC of 84.2%, 83.3%, 90.6%, 73.5%, 5.04, 
0.19 and 83.9, respectively. When choosing 132.7 ng/mL as the 
optimal cut-off value of serum LN, the sensitivity, specificity, 
PPV, NPV, LR+, LR- and AC were 71.9%, 80.0%, 87.2%, 60.0%, 
3.59%, 0.35% and 74.7, respectively. Details were shown in Table 
1, in which the performance of combinations of HA and LN by 
serial and parallel tests has also been shown respectively. Serial 
tests showed a perfect specificity and PPV of 100%, but at the 
same time sensitivity declined to 63.2% and LR+ increased to 
18.9. Parallel tests revealed a good sensitivity of 94.7%, NPV 
to 86.4%, while LR- declined to 0.08. In Table 2, some serum 
biochemical indexes were chosen as the predictors of significant 
fibrosis, none of which had shown high diagnostic performance.
Fig. 6 was an In/In plot of serum HA levels vs. serum LN 
concentration for all 87 CHB patients. In Fig. 6, the capability of 
two variables to discriminate completely between F2-F4 group 
and F0-F1 group was readily appreciable.
Fig. 1 - Box plots illustrating the distribution of HA values 
in controls and CHB patients against METAVIR fibrosis 
score (F0-F4). The line through the middle of each box 
represents median value, and the lower and upper borders 
of the box encompass the interquartile range.  
The error bars are the 5th and 95th percentiles.
Fig. 2 - Box plots illustrating the distribution of LN values 
in controls and CHB patients against METAVIR fibrosis 
score (F0-F4). The line through the middle of each box 
represents median value, and the lower and upper borders 
of the box encompass the interquartile range.  
The error bars are the 5th and 95th percentiles.
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Fig. 3 - Distribution of HA values in blood donors (controls) 
and CHB patients by fibrosis stage (F0-F1, F2-F4). The line 
through the middle of each box represents median value, 
and the lower and upper borders of the box encompass 
the interquartile range. The error bars are the 5th and 95th 
percentiles.
Fig. 5 - Receiver-operating characteristic (ROC) curves of 
serum HA and LN for diagnosis of significant fibrosis (F ≥ 2).
Fig. 6 - Serum HA vc serum LN concentrations in al 87 CHB 
patients with F0-F1 group (n = 30) or with F2-F4 group  
(n = 57).
Fig. 4 - Distribution of LN values in blood donors (controls) 
and CHB patients by fibrosis stage (F0-F1, F2-F4). The line 
through the middle of each box represents median value, 
and the lower and upper borders of the box encompass 
the interquartile range. The error bars are the 5th and 95th 
percentiles.
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Discussion
In China, especially in our province, chronic hepatitis B is 
one of the main causes of chronic liver disease. Therefore, 
it is clinically important to assess the progression of liver 
fibrosis for guiding clinical therapy.5 Liver biopsy fails to 
satisfy the more and more pronounced need for a rapid, safe 
and repeatable tool to monitor the fibrogenic progression of 
chronic liver disease. The ideal surrogate blood markers should 
enable repetitive measurement and be provided with other 
features, such as liver specificity, sensitivity for fibrogenesis/
fibrolysis, known half-life, known excretion route, synthesis 
by an identified cell source, etc.29 In this study, we aimed 
to assess the usefulness of serum HA and LN as biomarkers 
for predicting significant fibrosis in CHB patients with ROC 
curves. We found that as liver fibrosis progresses, there is 
a significantly increase of serum HA and LN concentrations 
correspondingly, and the highest values of HA and LN were all 
found in cirrhotic group (F = 4). In addition, HA and LN levels 
showed positive correlation with the stages of liver fibrosis in 
CHB patients (HA: r = 0.875, p < 0.001; LN: r = 0.610, p < 0.001). 
The results suggested that increased serum HA and LN levels, 
which are components of ECM, might indicate a consequence 
of chronic liver injury, leading to architectural changes in 
the liver parenchyma that causes liver fibrosis eventually.
As one component of ECM, HA has been described as a 
single parameter or as a major member of several fibrosis 
indexes for the noninvasive assessment of fibrosis in various 
chronic liver diseases in the past few years.6,10,11,19,24,30 
In our study, HA levels at its best cut-off value of 185.3 ng/mL 
for predicting significant fibrosis showed a high diagnostic 
performance, especially AUC-ROC of 0.909. For a certain 
marker, a value more than 0.9 for AUC-ROC means it is 
possible to differentiate between the two compared groups 
through this marker, while less than 0.7 for it means that it 
is not possible to differentiate between them.31 It suggested 
that HA as a biomarker could predict significant fibrosis at 
its optimal cut-off value.
In recent years, detention of serum LN was usually as a 
member of combined analysis of several fibrosis indexes 
rather than assay of only LN levels in liver fibrosis.1,10,11,32-34 
Our results showed that detection of serum LN concentrations 
was moderately accurate at the diagnosis of significant 
fibrosis (AUC-ROC of 0.815), but NPV was only 60%, which 
could be unacceptable for excluding significant fibrosis. 
Thought it may be explained due to the low number of 
patients, the diagnosis performance of LN was not better than 
that of HA, according to this study.
We also assessed the performance of combined HA and 
LN for predicting significant fibrosis. The results of serial 
tests showed a perfect specificity and PPV of 100%, LR+ up 
to 18.9, which could be acceptable for the definite diagnosis 
of significant fibrosis. At the same time, the results of 
parallel tests showed that sensitivity was raised to 94.7%, 
NPV to 86.4%, and LR- declined to 0.08, thus we could make 
a diagnosis for excluding significant fibrosis.
Variables AUC CI (95%) Cut-off 
(ng/mL)
 Se (%) Sp (%) PPV (%) NPV (%) LR + LR - AC (%) 
HA 0.909 0.847-0.971 185.3 84.2 83.3 90.6 73.5 5.04 0.19 83.9
LN 0.815 0.712-0.917 132.7 71.9 80 87.2 60 35.9 0.35 74.7
HA + LN (Serial tests) 63.2 100 100 58.9 18.9 0.38 75.9
(Parallel tests) 94.7 63.3 83.1 86.4 2.6 0.08 83.9
AUC, area under the curve; CI, confidence interval; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; 
LR+, likelihood ratio for positive test; LR-, likelihood ratio for negative test; AC, accuracy.
Variables AUC Cut-off  
(ng/mL)
Se (%) Sp (%) PPV (%) NPV (%) LR + LR - AC (%) 
ALT 0.698 62.5 (U/L) 69.2 58.6 70.7 52.6 2.4 0.41 65.7
AST 0.671 50.2 (U/L) 75.1 53.5 68.6 56.2 2.5 0.40 68.6
GGT 0.590 47.2 (U/L) 55.3 68.8 70.5 51.5 1.8 0.62 59.8
ALP 0.573 102.5 (U/L) 50.1 70.2 49.8 70.0 1.6 0.59 64.3
ALB 0.801 36.1 (g/L) 77.2 69.8 86.5 73.2 3.3 0.36 74.5
TBIL 0.711 25.2 (µmol/L) 58.9 80.2 83.9 49.3 3.0 0.37 64.1
AUC, area under the curve; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; LR+, likelihood ratio for 
positive test; LR-, likelihood ratio for negative test; AC, accuracy.
Table 1 - Diagnostic performance of the best cut-off point for serum levels of HA and LN in the prediction of significant 
fibrosis (F ≥ 2) for CHB patients
Table 2 - Diagnostic performance of serum biochemical indexes in the prediction of significant fibrosis (F ≥ 2) for CHB 
patients
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In conclusion, increased serum HA and LN concentrations 
showed positive correlation with the stages of liver fibrosis. 
Detection of serum HA and LN in prediction of significant 
fibrosis showed good diagnostic performance, which would 
be further optimized by combination of the two indices. HA 
and LN would be clinically useful serum markers for predicting 
significant fibrosis in patients with chronic hepatitis B, when 
liver biopsy is contraindicated.
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